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Abstract. Antisense transcription has long been recognized
as a mechanism involved in the regulation of gene expression.
Therefore, several human diseases associated with abnormal
patterns of gene expression might display antisense RNA-
mediated pathogenetic mechanisms. Such issue could be
particularly relevant for cancer pathogenesis, since deregulated
gene expression has long been established as a hallmark of
cancer cells. Herein, we report on a bioinformatic search for
antisense transcription in two cancer-associated regions of
human chromosome 6 (6q21 and 6q27). Natural antisense
transcripts (NATs) for several genes in both genomic regions
were predicted in silico and subsequently validated by
strand-specific RT-PCR. Detailed experimental validation by
quantitative real-time RT-PCR of five putative cancer related
sense-antisense transcript pairs revealed a single candidate
tumor suppressor gene (RPS6KA2) whose expression levels
display marked cancer-related changes that are likely mediated
by its antisense RNA in a breast cancer cell line model.
Introduction
Deletions in the long arm of chromosome 6 (6q) are among the
most frequent chromosome aberrations observed in several
human malignancies, such as non-Hodgkin's lymphomas,
melanoma and carcinomas of the mammary gland, ovary,
uterus, stomach, kidney and salivary gland (1-3). The involve-
ment of this chromosome in the pathogenesis of the above-
mentioned cancer types has been demonstrated by LOH
studies and chromosome-transfer assays, which led to the
identification of several regions of minimal deletion spanning
quite large segments of genomic DNA (4-6). More
specifically, independent studies have been published in
the last decade reporting a frequent involvement of the 6q21
and 6q27 genomic regions in cancer-related chromosomal
rearrangements (1,2), raising the hypothesis that one or
probably more tumor suppressor genes (TSGs) reside in these
regions. Several genes mapping in 6q21 and 6q27 have
been recently evaluated as putative TSGs. Among these,
the BLIMP1/PRDM1, RPS6KA2 and RNASET2 genes have
been implicated in the pathogenesis of single tumor types
(7-9). However, TSGs involved in the wide range of human
cancers associated with 6q21 and 6q27 rearrangements have
escaped detection to date despite intensive investigations (10-
12), the only exception being perhaps the HACE1 gene (13).
Interestingly, several genes from 6q27 that have been
recently evaluated as candidate TSGs did not show inactivating
coding mutations in cancer cells; rather, tumor-associated
downregulation of the corresponding transcripts was observed
for these genes (8-10), raising the possibility that they could
be involved in cancer pathogenesis acting as epigenetically
silenced class II TSGs. Quite unexpectedly, however, the
promoter methylation pattern for these genes was shown to be
unchanged in cancer cells, suggesting that other mechanisms
besides epigenetic modification should be envisioned to
explain the decreased expression levels observed for these
putative class II TSGs in cancer cells. 
Natural antisense transcripts (NATs) are endogenous tran-
scripts containing sequences complementary to other endo-
genous mRNAs, which are usually associated with a known
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function and are therefore defined as sense RNAs (14,15).
Following the completion of the human genome sequence,
several in silico studies, coupled with microarray analysis,
have demonstrated that the occurrence of NATs is quite
widespread in the human genome (16,17), with the most
recent surveys suggesting that up to 70% of the human
transcriptional units have natural antisense partners (18-20).
Antisense transcription has been involved in the regulation of
mammalian gene expression by means of several mechanisms,
including transcriptional interference, RNA-masking, RNA
editing, double stranded RNA (dsRNA)-dependent
mechanisms and antisense induced promoter methylation
(15). Significantly, aberrant gene expression has been
identified as an important molecular mechanism involved in
cancer progression (21,22). Moreover, the widespread DNA
hypomethylation usually observed in the cancer cell genome
has been recently proposed to trigger a global transcriptional
de-repression wave, thus generating a strong transcriptional
‘noise’ (23). By this mechanism, antisense transcripts with
aberrant regulation would be produced, some of which could
affect the function of overlapping TSGs and oncogenes,
ultimately paving the way for cancer progression. 
Indeed, a recent report by Yu et al showed that an
impressive proportion of the well known TSGs likely possess
nearby antisense RNAs (24). Moreover, antisense-mediated
downregulation for one of these TSGs (p15) was experi-
mentally confirmed in leukaemia cells. Thus, the hypothesis
of NATs acting as effectors of aberrant gene expression in
cancer cells is of particular interest and justifies a targeted
search for antisense transcription within genomic regions
which have been shown experimentally to harbour cancer-
related genes. However, although antisense-mediated
regulation of cancer-related genes has been analyzed in a
handful of reports focusing on a single locus (25-27), very
few studies have been devoted to a systematic search for
antisense genes putatively involved in cancer pathogenesis. 
Here, we report both in silico and experimental evidence
for the occurrence of antisense transcription in the 6q21 and
6q27 chromosomal regions. Interestingly, some of the NATs
identified in this work were shown to target ‘sense’ genes
whose function make them plausible candidates for cancer
pathogenesis. Indeed, detailed characterization of one such
sense/antisense pair provided compelling evidence for
antisense-mediated transcriptional deregulation of the
RPS6KA2 tumor suppressor gene, using mammary adeno-
carcinoma as an experimental model.
Materials and methods
RNA, cell lines and culture conditions. Total RNA from
normal human fetal brain and adult breast was purchased
from Stratagene and Invitrogen, respectively. Total RNA
from cultured cell lines was prepared with the TRI-reagent
(Sigma) following the manufacturer's instructions. The breast
cancer cell lines MDA-MB 213, MDA-MB 453, MCF-7,
HBL100, BT20 and T47D were cultured in Iscove's medium
supplemented with 10% fetal bovine serum.
Bioinformatic analysis. The in silico search for antisense
transcripts was performed with the ‘AntiHunter’ online anti-
sense detection tool (http://bioinfo.crs4.it/AH2.0/) (28). Briefly,
a catalogue of all genes available in the public human genome
annotation databases was first assembled for the two chromo-
somal regions of interest (6q21 and 6q27). The elements
retrieved included transcript identifiers, gene coordinates,
strand of the corresponding transcripts, description of the gene
product, informations on mouse orthologs and expression
pattern. The genomic sequences corresponding to the annotated
genes were retrieved with an extension of 1500 base pairs at
both ends of the annotated gene transcript. We then used a
series of perl scripts to produce a relational ‘Antisense’
database, collecting all the gene-related information. The
AntiHunter search output included a variety of information
related to the putative antisense ESTs, including accession
number, match significativity, strand identity, presence of
splice site signals and expression pattern. To further refine
the results, we used the CAP Assembler (http://bio.ifom-ieo-
campus.it/cap) to produce contigs of antisense EST sequences
that were remapped to the genome assembly consensus. We
then installed a local copy of the GBrowse Generic Genome
Browser (http://www.gmod.org/ggb/) and linked it with the
Antisense database, to provide an intuitive way for the location
of the antisense EST sequences in the genome context. A
database with the results of the bioinformatics procedure is
freely available at the web link http://bio.ifom-ieo-campus.it/
antisense.
Strand-specific and quantitative real-time RT-PCR. Total
RNA was extracted using TRI-Reagent (Sigma) following
the manufacturer's protocol. For all RT-PCR reactions
performed, RQ-DNAse (Promega) treatment of RNA samples
was carried out and a PCR assay on DNAse-treated RNA
was performed to rule out DNA contamination. One micro-
gram of total RNA was used for the strand-specific RT-PCR
assays. The same primer pair was used to detect both sense
and antisense transcription from a single locus by selecting it
from the overlapping region between the antisense ESTs and
the genomic DNA or the mRNA of the corresponding sense
gene (with reference to the NCBI release 34). When an
antisense EST contig was present, the best EST vs. genome
match was selected for primer selection. Primer sequences
for all sense-antisense gene pairs that have been experimentally
validated are available on request.
Strand-specific RT-PCR reactions were carried out using
the Sigma DuraScript™ RT-PCR HSRT-100 kit in a final
reaction volume of 25 μl. Four reactions were set up for
every gene to be tested: i) retrotranscription of the antisense
transcript: the forward primer only was included during the
retrotranscription step; ii) retrotranscription of the sense
transcript: the reverse primer only was included during the
retrotranscription reaction; iii) positive control: both primers
have been used (0.5 μl of a 50 μM solution) but samples
have been introduced in the thermocycler only during the
PCR phase. Genomic DNA was used as a template instead of
RNA; iv) negative control: both primers have been added
to the reaction mix (1 μl of a 10 μM solution) but no RNA
template was included to the reaction mix.
In all four reactions, both sense and antisense primers
were added to the reaction mix before the PCR reaction
(0.5 of a 50 μM solution). PCR conditions were as follows:
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the retrotranscription step was performed at 50˚C for 50 min.
Thereafter, a single 5-min step at 94˚C was performed,
followed by 35 cycles of amplification with 30 sec at 94˚C
(denaturation), 30 sec at a variable annealing temperature,
depending on the single primer pair (annealing) and 1 min at
72˚C (extension), and a single final extension step of 5 min at
72˚C. PCR products were analyzed by agarose gel electro-
phoresis with standard buffers and conditions.
For quantitative real-time RT-PCR assays, the Primer
Express Software version 2.0 program (Applied Biosystems)
was used to design, for each gene to be tested, forward and
reverse primers having the same annealing temperature and
GC content. Total RNA (1 μg) together with each specific
primer at a final 0.5 μM concentration, was heated at 65˚C
for 5 min, chilled on ice and incubated at room temperature
for 10 min; the RNA was then retrotranscribed (in triplicate)
using the High Capacity cDNA synthesis kit (Applied Bio-
systems) for 2 h at 37˚C. Real-time RT-PCR was performed
on ABI PRISM 7000 with Power SYBR green PCR Master
Mix (Applied Biosystems) following the manufacturer's
instructions. The sequence of all primer pairs used are available
on request. Following a DNA polymerase activation step at
95˚C for 10 min, samples were denaturated at 95˚C for 12 sec
and annealed/extended at 60˚C for 1 min, for 35/45 cycles.
Fluorescent signals generated during PCR amplification were
monitored and analyzed with ABI PRISM 7000 SDS software
(Applied Biosystems). Comparison of the amount of each
gene transcript among different samples was made using
ß-actin as reference. The amount of target RNA, normalized
to the endogenous reference gene, was calculated by means
of the difference-in-threshold-cycle parameter (ΔCt). 
RNAi and transcript overexpression for RPS6KA2 sense/
antisense gene pair. BT20 and T47D cells were transfected
for RNA interference either once with 100 nM or twice (at
24- or 48-h time interval) with 50 nM RPS6KA2-specific
On-Target plus Duplex J-004663-06 or J-004663-07
scrambled control oligo (Dharmacon) using Oligofectamine
(Invitrogen Corp.) according to the manufacturer's instructions.
The cells were then collected at 48h post-transfection for
real-time RT-PCR analysis. A 674-bp DNA fragment cor-
responding to an experimentally confirmed overlapping
region between RPS6KA2 and its antisense transcript
(genomic coordinates: 166.919.038-166.919.711 - UCSC
assembly March 2006) was cloned by RT-PCR in pcDNA3
(Invitrogen) with an orientation resulting in transcription of
the antisense RNA. BT20 cells were seeded two days
before performing cotransfection with pcDNA3-antisense
or empty vector together with pCMV-GFP (5:1) as a reporter
construct. Two days after transfection with Fugene (Roche),
cells were collected and GFP-sorted in order to improve the
detection of transfected genes. Real-time RT-PCR for
RPS6KA2 sense/antisense RNA was performed as described
above.
Microarray data analysis. Expression data for 59 lymph node-
negative (N0) estrogen receptor-positive (ER+) breast cancer
patients, previously generated with Affymetrix HG-U133 chip
A+B (29,30), were extracted for the RPS6KA2 sense (probeset:
204906_AT) and antisense (probeset: 225210_S_AT) tran-
scripts. Raw data was median centred and log2 converted, in
order to determine the reciprocal correlation between the two
genes (positive: up/up or down/down; negative: up/down or
down/up). P-value was calculated with Fisher's exact test
with the JMP 7.0.1 software (SAS).
Results
In silico detection of NATs from 6q21 and 6q27. As a first step
towards the identification of sense-antisense transcript pairs
from 6q21 and 6q27, we performed an extensive in silico
search for putative NATs from both chromosomal regions.
To this aim, a collection of well-annotated genes was retrieved
from public human genome annotation resources and
assembled into a dedicated database. A total of 101 genes
(61 genes from 6q21 and 40 genes from 6q27) were reported
on both genomic regions; the genomic DNA sequence
corresponding to these annotated genes was therefore retrieved,
transferred into our database and used as the input data for
the identification of antisense transcripts by means of the
AntiHunter web tool.
This analysis produced an initial output of 24 genes (20
from 6q21 and 4 from 6q27) for which antisense EST
sequences were reliably detected in silico (Table I). A total
of 182 antisense ESTs were found for the 4 genes in 6q27,
whereas 453 antisense ESTs were detected for the 20 genes
in 6q21. All 24 genes had corresponding RefSeq sequences
besides AK094715 and c6orf208, which represent in silico
predicted genes. Analysis of all antisense ESTs with CAP
Assembler showed that it was often possible to assemble a
single contig represented by several EST sequences internal
to a major longer antisense EST, further suggesting that bona
fide antisense RNAs were detected.
The re-alignment of all antisense ESTs on the human
genome sequence allowed us to deduce the pattern of overlap
between the putative sense and antisense transcript pairs at
each locus. Among the 24 sense genes for which AntiHunter
predicted the occurrence of antisense transcription, 14 (58%)
turned out to share at least one exon with their putative anti-
sense partner, thus representing sense-antisense (SA) clusters
according to the definition of Chen et al (18). For the remaining
10 genes (42%) the inferred sense-antisense pattern of overlap
did not include any exon, therefore these transcript pairs were
classified as non-exon overlapping bidirectional clusters
(NOBs) (Table I).
The alignment of the in silico predicted antisense ESTs
on the human genome showed that the majority of these EST
sequences were indeed derived from human chromosome 6,
with an identity percentage ranging from 97 to 99%. This
was taken as an indication that most antisense ESTs predicted
by the AntiHunter analysis likely represent cis-NATs. Many
of the significative alignments to non-6 chromosomes were
due to repetitive elements, therefore the corresponding ESTs
were not considered for further analysis. However, for a few
genes in the two chromosomal regions under investigations it
was not possible to determine unambiguously the locus from
which the predicted NATs were transcribed, since the latter
produced alignments with identical scores in two or more
genomic regions. Thus, some of these antisense transcripts
could actually represent trans-NATs (Table I). 
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The list of genes from 6q21 and 6q27 for which we
predicted antisense transcription in silico was compared with
the recent on-line catalog of sense-antisense pairs from the
Laboratory of Computational Biology at LICR São Paulo,
Brasil (http://www.compbio.ludwig.org.br/sense-antisense/)
(31). We found evidence for antisense transcription in the
LICR database for 14 out of 24 genes from our list, providing
a further bioinfomatic support for our results. Moreover, we
identified from the UCSC genome browser six Acembly
antisense transcripts that reinforced the evidence initially
derived from single antisense EST sequences. 
Two of the RefSeq genes under investigation (PHF10
and c6Orf120) were found to overlap at their 3' UTRs, thus
representing a couple of sense-antisense pair between two
protein coding genes (although the gene product from the
latter has not yet been experimentally confirmed). Moreover,
using the source databases (UCSC, Aceview and LICR)
together with the ORF Finder tool (http://www.ncbi.nlm.nih.
gov/gorf/gorf.html) to analyze the coding potential of each
putative NAT, we found a potential ORF in the antisense tran-
script of seven sense genes (ARMC2, FYN, PREP, QRSL1,
SMPD2, TUBE1, RPS6KA2). For all other sense genes, the
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Table I. Summary of 24 annotated genes from 6q21 and 6q27 for which antisense transcription was predicted in silico by
AntiHunter.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene RefSeq Human genomic Type of sense- Region of the sense gene Antisense  Evidence for Evidence 
symbol sequence antisense overlapping with RNA in  coding anti- for trans-
coordinatesb gene pair antisense RNA the mouse sense RNA NATs
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
6q21
AK094715 - 109664510-109698413 NOB 2nd intron
ARMC2 NM_032131.4 109276318-109401877 NOB 8th intron ● ●
ATG5 NM_004849.2 106739045-106880388 AS 6th intron and 3' UTR ● ●
CD164 NM_006016.3 109794414-109810340 AS 3' UTR ●
CDC2L6 NM_015076.3 111037874-111243530 NOB 2nd and 4th intron
FYN NM_002037.3 112089178-112301320 AS 4th and 12th intron, ● ● ●
11th and 12th exon
MICAL NM_022765.2 109871959-109883883 AS Exon 23 to 3' UTR
OSTM1 NM_014028.3 108469306-108502634 AS 3' UTR ●
PDSS2 NM_020381.3 107580454-107887472 NOB 4th intron ● ●
POPDC3 NM_022361.3 105712470-105734563 NOB 1st intron ●
PRDM1 NM_001198.3 106640888-106664507 NOB 3rd intron ●
PREP NM_002726.3 105832199-105957662 AS 13th exon and 14th intron ●
QRSL1 NM_018292.3 107184146-107222103 NOB 9th intron ● ● ●
REV3L NM_002912.3 111726927-111911107 AS 1st, 4th, 12th and 27th intron ●
RTN4IP1 NM_032730.4 107125596-107184066 AS 3' UTR
SEC63 NM_007214.4 108295653-108386175 AS 1st and 4th intron; 3' UTR ●
SMPD2 NM_003080.2 109868624-109871815 AS 5' UTR ● ●
SNX3 NM_003795.3 108639410-108689156 AS 3' UTR ● ●
TRAF3IP2 NM_147686.1 111986836-112034014 AS 1st , 2th to 8th intron ●
TUBE1 NM_016262.3 112498673-112515349 AS 3' UTR ● ●
6q27
C6orf208 - 169932342-169944894 NOB 1st intron
PHF10a NM_133325.2 169845926-169866031 AS 9th intron to 10th exon;  ● ● 
11th intron to 12th exon
RPS6KA2 NM_001006932.1 166742844-167195761 NOB 1st , 6th, 7th intron ● ● ●
SFT2D1 NM_145169.1 166653506-166675981 NOB 1st intron
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
The genes marked in bold were selected for further experimental validation on the basis of bioinformatic evidence for antisense transcription also in the
mouse genome. Each sense-antisense gene pair was classified either as antisense-sense exon overlapping (AS) or non-exon overlapping bidirectional (NOB)
gene pair, according to the inferred pattern of overlap between the sense and antisense transcripts. The region in the sense gene which was chosen for PCR
detection of antisense transcription is underlined for those gene pairs where several regions of overlap between sense and antisense transcripts were found.
Evidence for the putative occurrence of trans-NATs was obtained by genome-wide BLAT analysis with the nucleotide sequence of each putative antisense
EST. aThe antisense gene for PHF10 is itself a RefSeq gene (c6Orf120 -  see text). bUCSC assembly Mar 2006.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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corresponding in silico predicted antisense transcripts likely
represent bona fide non-coding antisense genes. 
Thus, the final result of our in silico analysis was an
annotated list of 24 genes for which evidence for the
occurrence of antisense transcription was found (Table I). In
order to define a list of biologically relevant candidate
NATs among those detected by AntiHunter, the occurrence
of antisense transcription for both the human and murine
loci was investigated. This criterion was chosen since
evolutionarily conservation of sense-antisense transcript pairs
has recently been shown to represent a reliable hallmark of
functional relevance for antisense-mediated gene regulation
(33,34). In 6q27, 2 out of the 4 sense genes for which antisense
ESTs were found gave evidence for a corresponding antisense
transcript also in the mouse genome. Similarly, in the 6q21
region, 14 out of 20 sense genes showed the presence of an
antisense transcript in the mouse (Table I). These 16
evolutionarily conserved and putative antisense-regulated
genes were therefore selected for primary biological validation
of antisense transcription by means of strand-specific RT-PCR.
Experimental validation of candidate NATs. For each selected
sense-antisense gene pair, a couple of primers was designed
as described in Materials and methods to detect transcription
from both strands on each locus. 
Since a large fraction of the human genome is known to
be expressed in fetal brain (35), RNA from this tissue was
chosen as the template for RT-PCR assays. Moreover, total
RNA was used rather than a poly-A+ fraction to perform this
analysis, since most NATs have been recently reported to
represent non-polyadenylated transcripts (36).
As a control, we included in our strand-specific RT-PCR
assays two genes from 6q21 (FOXO3A and CDK11) and two
from 6q27 (RNASET2 and FOP) for which Antihunter did
not detect antisense ESTs. The results of the validation assay
is shown in Fig. 1: eleven antisense transcripts on a total of
16 genes tested (69%) were detected using just a single tissue
as a source of RNA for RT-PCR reactions. As expected, the
four control genes for which we could not find in silico
evidence of antisense transcription produced an expected
amplification band with the sense strand-specific primer only
(two of these four genes, FOXO3A and RNASET2, are
included in Fig. 1). 
Strikingly, for most gene pairs analyzed we observed
expression of both sense and antisense transcripts in human
fetal brain RNA. Such co-expression pattern was also observed
for 5 sense-antisense NOB gene pairs (POPDC3, PRDM1,
QRSL1, PDSS2 and RPS6KA2), whose overlapping sequences
did not involve known exons from the sense gene. Therefore,
since the same primer pair was used to detect transcription
from both DNA strands, the sense transcripts detected by
RT-PCR for these NOB pairs likely represented either a
novel, previously unrecognized exon from the sense gene or
its pre-mRNA. Indeed, the latter event was not completely
unexpected since, as mentioned before, total RNA rather than
the poly-A+ fraction was used as a template for our RT-PCR
assays. Accordingly, when the RT-PCR assays were repeated
using exon-specific primers to detect the sense transcript,
expression of the mature sense transcript for all six NOB
pairs was confirmed (data not shown). 
An issue that has not been given much attention in most
studies of antisense transcription is the possibility that RNA
self-priming events during the retrotranscription step could
result in the false appearance of putative antisense transcripts
in an RNA sample of interest. These spurious events can be
easily revealed by omitting the strand-specific primer during
the retrotranscription step of an RT-PCR reaction. Therefore,
a further strand-specific RT-PCR assay with a control
reaction (in which the antisense-specific primer was omitted
in the retrotranscription step) was carried out for all the sense
genes for which antisense transcription was experimentally
confirmed. Only 2 out of the 11 selected genes (PDSS2 and
SNX3) gave clear evidence of self-priming events, casting
some doubt over the real occurrence of their corresponding
antisense transcripts (data not shown).
Our strand-specific RT-PCR assays were carried out with
fetal brain RNA in order to experimentally detect a number
of NATs as large as possible. However, since fetal brain
represents a complex mixture of several different cell types,
we could not be certain that the observed expression of both
sense and antisense RNAs in this tissue truly represented
co-expression of both transcripts within a single cell type.
This is an important issue, since regulation of gene expression
by antisense-mediated mechanisms can only take place when
both transcripts of a sense-antisense pair are present in the
same cell. Furthermore, fetal brain is a normal tissue, while
our study was targeted to the identification of sense-antisense
gene pairs with some relevance to cancer pathogenesis. To
address both issues, we decided to evaluate the expression
pattern of 5 sense-antisense transcript pairs in a panel of six
mammary cancer cell lines (MDA-MB231, MDA-MB 453,
MCF7, HBL100, BT20 and T47D) by strand-specific RT-PCR.
The 5 gene pairs were selected from our list of in silico
predicted, experimentally confirmed sense-antisense tran-
scripts on the basis of the established or putative candidacy
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Figure 1. RT-PCR validation for in silico predicted NATs. AS, antisense
transcript; S, sense transcript; +, positive control (total human genomic
DNA); -, negative control (no RNA template). A black dot highlights sense
genes for which an antisense transcript was experimentally detected.
FOXO3A and RNASET2 are control genes for which no antisense transcripts
were predicted by AntiHunter.
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as a cancer-related gene for the sense transcript (Table II).
Significantly, for all 5 genes the co-expression of both sense
and antisense transcripts previously observed in human fetal
brain was confirmed in most cell lines analyzed, thus demon-
strating that these five loci do really express in a single cell
type both sense and antisense RNAs, which therefore have the
potential to interact functionally. Fig. 2 shows the expression
data for a single cell line (HBL-100) in which co-expression
of both sense and antisense transcripts for all five gene pairs
was observed. 
Quantitation of sense and antisense RNA levels in a panel of
cancer cell lines. The co-expression in different mammary
cancer cell lines of both sense and antisense transcripts for
the above-mentioned cancer-related genes prompted us to
evaluate the biological relevance of this observation.
To this aim, quantitative real-time RT-PCR assays were
performed on the same cancer cell line panel described above
and on a normal breast tissue sample, in order to detect
putative changes in the relative expression levels of sense
and/or antisense transcripts. The results of this analysis are
shown in Fig. 3. For the five genes tested, different patterns
of changes in the expression levels in normal versus cancer
cells were observed for either the sense or the antisense
transcript (or both). For example, expression of both sense
and antisense RNA from the TRAF32IP gene turned out to
be significantly increased in all cancer cell lines, when
compared to the non-neoplastic counterpart. Since both
sense and antisense RNA levels were increased propor-
tionally, the observed changes in the RNA levels from both
DNA strands at this locus did not translate in a significant
change in the sense/antisense transcript ratio in the cancer
cell lines panel. A similar trend was observed for the FYN
gene, where a significant change in the sense/antisense
transcript ratio was observed in two cell lines only.
As far as the TUBE1 gene is concerned, although sig-
nificant changes in the levels of either sense or antisense
transcripts were found in some tumor cell lines, a clear trend
did not emerge when the ratio between sense and antisense
expression levels was evaluated. 
However, the expression pattern observed for the remaining
two genes included in this analysis (PHF10 and RPS6KA2)
proved much more interesting. Although we noted a trend
for a cancer-specific upregulation of the antisense RNA for
PHF10, the sense transcript (e.g., the PHF10 transcript itself)
showed a much more dramatic increase in all cancer cell lines
examined. Therefore, an increased sense/antisense ratio was
observed in 5 out of 6 cell lines for this gene. Although this
observation does not necessarily imply a reciprocal regulation
between the sense and antisense transcript, the marked
upregulation of PHF10 sense RNA in all tumor cell lines
examined points to a putative oncogenic role for this gene.
Even more interesting were the results obtained with the
RPS6KA2 transcript pairs. In this case, the observed down-
regulation of the sense transcript in 6 out of 7 cancer cell
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Table II. Genes analyzed by strand-specific RT-PCR and quantitative real-time PCR.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene Location OMIM entry Gene product's function
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
FYN 6q21 *137025 Membrane-associated tyrosine kinase that has been implicated in the control of cell growth
TUBE1 6q21 *607345 Tubulin epsilon. The gene product localize within the centrosome of dividing osteogenic sarcoma cells
in a cell cycle-dependent manner
TRAF3IP2 6q21 *607043 The gene product interacts with TRAF proteins (tumor necrosis factor receptor-associated factors)
and either I-kappa B kinase or MAP kinase to activate either NF-kappaB or Jun kinase
RPS6KA2 6q27 *601685 Serine/threonine kinases that phosphorylates various substrates, including members of the mitogen-
activated kinase (MAPK) signalling pathway. Implicated in controlling cell growth and differentiation
PHF10 6q27 - Predicted ORF encoding a protein with two zinc finger domains
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Expression data for these genes were obtained in normal breast and a panel of breast cancer cell lines, on the basis of the predicted or experimentally
confirmed involvement for these genes in cellular or biochemical processes related to cancer.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 2. Co-expression of sense and antisense transcripts for five putative
cancer-related sense genes within a single cell type (HBL-100 breast cancer
cell line) assessed by strand-specific RT-PCR. Lane 1, negative control for
antisense transcript; lane 2, negative control for sense transcript; lane 3,
molecular weight marker; lane 4, antisense transcript; lane 5, sense transcript.
The different molecular weight observed for the PHF10 and RPS6KA2
transcripts is due to the fact that different primer pairs were used to detect
the sense and the antisense transcript for these genes.
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lines with respect to the normal tissue sample was mirrored
by a parallel increase of the corresponding antisense RNA in
the same cell lines (for example, normal breast tissue and the
BT20 cell line displayed both the higher expression level of
sense RNA and the lowest expression level of the antisense
RNA within the whole samples panel, whereas the opposite
trend was observed for the T47D cell line). 
When the sense/antisense expression ratio was examined
for this locus, all cancer cell lines showed a significant
decrease of this value when compared to the normal breast
tissue, with the exception of the BT20 cell line. These results
strongly suggest the occurrence of sense-antisense reciprocal
gene regulation for this locus. 
The antisense transcript for the RPS6KA2 gene could not
be unambiguously assigned in the genome, since it produced
two alignments with identical scores on chromosomal bands
6q27 (where the RPS6KA2 locus reside) and 15q25.2.
Indeed, whereas in the latter chromosomal band the
RPS6KA2 antisense transcript was mapped to a 1200-bp
region representing the full-length transcript of the FAM102A1
gene, a processed FAM103A1 pseudogene with antisense
orientation to the RPS6KA2 gene was also found in 6q27.
Therefore, the experimentally detected RPS6KA2 antisense
RNA could derive from either the spliced transcript of the
FAM103A1 gene on chromosome 15 (thus representing a
trans-NAT) or, alternatively, from the unspliced RNA of the
FAM103A1 processed pseudogene on chromosome 6 (thus
representing a cis-NAT) or perhaps from both loci.
To further investigate the functional role of RPS6KA2's
antisense RNA in the regulation of the sense transcript levels,
we decided to experimentally manipulate the intracellular
levels of both sense/antisense transcripts in two of the above-
mentioned cell lines (BT20 and T47D).
As shown in Fig. 4A, knocking down the RPS6KA2 sense
transcript levels by means of RNA interference in the ‘high-
expressing’ cell line BT20 triggered a significant increase in
the levels of the corresponding antisense transcript, as
assessed by quantitative real-time RT-PCR. Unfortunately,
the reciprocal experiment (i.e. knocking down the RPS6KA2
antisense gene transcript in the ‘high-expressing’ T47D cell
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Figure 3. Quantitative real-time RT-PCR for both sense and antisense transcripts from five putative cancer-related genes. The PCR assay was performed as
described in Materials and methods. For each gene, the expression of either the sense or the antisense transcript (left and middle panels) in several breast cancer
cell lines was compared to that observed in a normal breast control sample following normalization with the ß-actin reference gene. The sense/antisense fold
change ratio for cancer cell lines vs. normal breast tissue was then calculated (right panel) by using as a reference the ratio between the sense and antisense
transcripts in the normal breast control sample, which was arbitrarily given a value of one. Bars indicate means with SE; *p<0.05; **p<0.01. Statistical analysis
was carried out with One-way ANOVA. Lane 1, normal breast; lane 2, MDA-MB231; lane 3, MDA-MB 453; lane 4, MCF7; lane 5, HBL100; lane 6, BT20;
lane 7, T47D.
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line) was not informative. For unknown reasons we were
not able to achieve a significant silencing of the antisense
transcript by RNAi in this cell line, despite several attempts
with a wide range of experimental conditions (data not
shown).
We thus turned again to the BT20 cell line, and decided
to see whether overexpression of the RPS6KA2 antisense
RNA (whose expression level is very low in this cell line)
was associated with a decrease in the intracellular levels of
sense transcript. Indeed, a marked downregulation of the
RPS6KA2 sense gene expression was observed by real-time
RT-PCR in cells transfected with an antisense-expressing
vector (Fig. 4B), suggesting antisense-mediated silencing as
a molecular mechanism for the regulation of the intracellular
levels of the RPS6KA2 transcript.
On the basis of these data, we hypothesized that
reciprocal regulation of the sense/antisense transcript pair for
the RPS6KA2 locus may also occur in primary human cancer
specimens. Therefore, based on our previous results with
human breast cancer cell lines, we extracted the data for
RPS6KA2 sense (probeset: 204906_AT) and antisense
transcript (probeset: 225210_S_AT) from a panel of 59
breast cancer patients whose transcript profile was previously
analyzed on a breast carcinoma microarray (29,30). As shown
in Fig. 4C, the RPS6KA2 transcript and its antisense RNA
proved to be negatively correlated with a high confidence
(p=0.0092) in 42 out of 59 patients (71%). Taken together,
this evidence further supports the hypothesis of functional
regulation of sense/antisense transcript for RPS6KA2 in breast
cancer. 
Significantly, RPS6KA2 was recently reported as a tumor
suppressor gene for sporadic epithelial ovarian carcinoma,
thus strengthening its functional relevance for the pathogenesis
of several cancer types (8). Monoallelic expression for this
gene was also reported by the same authors, providing an
indirect support for the occurrence of antisense RNA-mediated
regulation of this gene, since monoallelic expression of several
imprinted genes within mammalian genomes has been
functionally linked to the presence of antisense transcription
(37).
A further characterization of the sense-antisense transcript
interaction in a wide range of normal and neoplastic tissues is
therefore warranted for this gene, in order to better define
both the molecular mechanisms by which its expression is
downregulated in cancer cells and its involvement in a wider
range of cancer types besides ovarian and breast carcinomas.
Discussion
The recent completion of the human genome sequence
provided the scientific community with new tools to better
understand the mechanisms of gene regulation at the genomic
level. In this research area, the growing interest that has been
recently devoted to the study of natural antisense transcript
(NATs) stems based on two arguments: first, recent in silico
and experimental evidence suggests that a significant fraction
of the mammalian transcripts represents NATs (18-20).
Second, there is increasing evidence that NATs can provide
the cell with a versatile tool for carrying out gene regulation
by means of several mechanisms. Cancer is, among other
diseases, one of the most important pathological conditions
which have been proven to be highly sensitive to abnormal
gene expression patterns.
Indeed, several molecular mechanisms of aberrant gene
expression such as gene amplification, epigenetic silencing
and altered gene dosage due to aneuploidy have been defined
as important contributors to tumor progression (21,38,39).
Moreover, experimental and bioinformatic evidence has been
recently reported to suggest the involvement of antisense
transcription in the pathogenesis of cancer. For instance,
by using prostate cancer as a model, Reis et al reported an
increased expression of intronic transcripts correlating to the
degree of tumor differentiation when compared to non-intronic
regions. Strikingly, a significant fraction of these intronic
transcripts was represented by antisense RNAs (40). As a
further example, the longer than average length of 5'-UTR
and first exon which has been recently reported in genes
which have overlapping antisense transcripts in the 5' region
and are known to be silenced in human cancer has been taken
as indirect evidence that antisense transcription could play a
pivotal role in such epigenetic phenomenon (41).
Finally, a recent study by Yu et al provided striking
evidence for the occurrence of antisense RNA-mediated
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Figure 4. Quantitative real-time RT-PCR for both RPS6KA2 sense and
antisense transcripts in the BT20 mammalian cancer cell line following
either RNAi against the sense transcript (A) or antisense transcript over-
expression (B). The PCR assay was performed as described in Materials and
methods. For each gene, the expression of either the sense or the antisense
transcript was normalized with the ß-actin reference gene. Bars indicate means
with SE. C, Expression data for RPS6KA2 sense (probeset: 204906_AT)
and antisense (probeset: 225210_S_AT) transcript on a panel of 59 breast
cancer patients. Raw data were median centered and log2 converted. P-value
(0.0092) was calculated with Fisher's exact test (JMP 7.0.1)
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regulation as a mechanism to control the expression of known
tumor suppressor genes (24).
Altogether, the above-mentioned data suggest that anti-
sense-mediated regulation of gene expression has been
largely under-estimated in the past as a putative molecular
mechanism involved in cancer pathogenesis or progression.
Indeed, as far as the identification of tumor suppressor genes
is concerned, the long established strategy of using LOH
data combined with mutation screening to map and identify
these cancer-related genes has proven unsuccessful in many
instances (42), thus suggesting that novel conceptual avenues
are needed to identify most of the still elusive oncosuppressor
genes scattered throughout the human genome. Significantly,
antisense-mediated gene silencing has been recently shown
to provide a powerful tool for the identification of tumor
suppressor genes. For instance, Li et al were able to demon-
strate the oncosuppressive role for the utrophin gene by a
functional assay based on antisense-mediated suppression of
the endogenous sense gene transcript from this locus in a
cancer cell line (43). Despite this suggestive evidence, to date
little effort has been devoted to a better understanding of the
role that antisense-mediated regulation of gene expression play
in the pathogenesis of cancer.
In this work, we predicted in silico a significant number
of putative NATs for several annotated genes mapping to
two chromosome 6 genomic regions whose alterations are
associated with a wide range of human malignancies. We
were able to experimentally confirm antisense transcription
for 69% of the predicted sense-antisense gene pairs by means
of strand-specific RT-PCR with just a single tissue (human
fetal brain) as a source of template RNA. 
Within our panel of experimentally validated sense/anti-
sense gene pairs, the exon overlapping (AS) and non-exon
overlapping (NOBs) categories were represented with similar
frequencies. This was not an unexpected result, since an
increasing number of recent whole-genome studies have
reported the widespread occurrence of intronic antisense
transcription in the human genome (44). Co-expression of
both members of a sense-antisense gene pair was observed
with a high frequency in our panel of candidate genes,
suggesting that some of these gene pairs could be engaged in
antisense-mediated cross-regulation in vivo.
Regarding this issue, Chen et al have recently proposed
three main criteria to define sense-antisense gene pairs for
which antisense-mediated control of gene expression is
likely to occur (33). Two of these criteria (i.e. evolutionary
conservation of a sense-antisense gene pair and coexpression
of sense-antisense transcripts pair within the same cell type)
were shown to apply to several sense-antisense gene pairs
identified in this work, supporting the notion that some of
these NATs could indeed play a role in the regulation of the
expression levels of the sense partner. Interestingly, both
criteria were also fulfilled for 5 genes potentially involved in
cancer pathogenesis (or whose annotations predict a role in
tumorigenesis) (Table II).
Regarding the third criterion defined by Chen et al
(inverse expression levels for the sense and antisense
transcripts within a particular locus), our quantitative real-time
PCR assays strongly suggested that such a phenomenon
actually occurs for one of the five putative cancer-related
genes (RPS6KA2) that were investigated in detail, thus
defining this gene as a strong candidate for antisense RNA-
mediated gene regulation. Indeed, RNAi assays coupled to
standard gene overexpression studies provided clear evidence
for the occurrence of regulatory crosstalk between RPS6KA2
sense and its antisense transcript into a single breast cancer
line. Whether such regulatory mechanisms occur in other
breast cancer cell lines is currently unknown, and our future
work will be focused to this issue. 
It is noteworthy that RPS6KA2 was recently described as
a tumor suppressor gene for sporadic ovarian carcinoma (8),
thus providing further support for the relevance of this gene in
cancer pathogenesis. Indeed, our preliminary results on a panel
of human ovarian cancer cell lines suggest that antisense-
mediated regulation of this gene likely takes place also in the
setting of this cancer type (LM and FA, unpublished data). The
fact that RPS6KA2 was recently reported as a tumor
suppressor involved in a cancer type (ovarian carcinoma)
different from the one investigated here strongly supports the
usefulness of antisense transcription mapping in cancer-related
genomic regions as a tool for the identification of genes
whose changes in expression levels are somehow related to
cancer development or progression. At the same time, the
antisense-mediated regulation of the RPS6KA2 reported in
this work could contribute to shed more light on the molecular
mechanisms involved in the functional inactivation of this
gene in human cancer.
Our data allowed us to draw a striking parallel with those
recently reported by Yu et al (24) in several respects. First,
an inverse expression between the transcript levels of a TSG
and its NAT was observed in our study on both cancer cell
lines and primary tumor samples. Second, forced antisense
overexpression produced a marked decrease in the corre-
sponding sense transcript in vivo. Thus, RPS6KA2 can be
defined as a bona fide member of the growing family of TSG
whose cancer-associated expression changes are mediated by
antisense transcription.
As far as the molecular mechanism by which antisense-
mediated regulation of RPS6KA2 gene expression takes
place in vivo, it is worth noting that this sense/antisense gene
pair does not show any exon overlap. Therefore, if the
underlying regulatory mechanism requires dsRNA formation
(as the results of our antisense overexpression assay suggests)
then an interaction between RPS6KA2 pre-mRNA and its
antisense transcript has to be postulated. However, other
known dsRNA-independent regulatory pathways, such as
epigenetic anti-sense-mediated silencing or transcriptional
collision between two converging RNA polymerase II
complexes (15) might also be invoked to explain the
observed inverse expression pattern within this gene pair.
Such issue is currently being investigated in our laboratory.
In conclusion, the combination of in silico analysis and
primary validation of antisense transcripts allowed us to
identify a subset of genes that display antisense transcription
and are annotated with molecular or cellular functions
compatible with a role in cancer pathogenesis. Among these
genes, RPS6KA2 stood out as a plausible antisense-regulated
TSG. To our knowledge, this is one of the first attempts to
get a comprehensive picture of sense-antisense transcription
from a particular cancer-related genomic region. We believe
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that a more widespread application of this strategy will
provide an important contribution to the long-term goal of
producing a molecular blueprint of human cancer.
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